On the fly News and insights, exclusive to thefly.com



$9.25 /

+0.23 (+2.55%)


Prescience Point takes activist stake in MiMedx, sees 'chronic undervaluing'

Prescience Point Capital Management disclosed a 7.9% stake in MiMedx Group, which represents over 8.7M shares. The filing with the SEC allows for activism. Prescience believes that the company's management and board "have ineffectively communicated the value" of the Amniofix injectable product to the investment community. The firm believes this has resulted in the "chronic undervaluing" of MiMedx equity by the public markets. Prescience believes the value of the company's pipeline of clinical trials for Amniofix "far exceeds" that of its advanced wound care business. Prescience Point intends to engage in discussions with management and the board "to bring about positive changes in the Issuer's messaging to the investment community." Shares of MiMedx are up 4% to $9.43 in midday trading.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.